Sector News

Valeant nears $2B sale of its Bausch & Lomb surgery business

June 6, 2017
Life sciences

Valeant Pharmaceuticals, on a mission to raise cash and pay down debt, is in talks to sell its Bausch & Lomb eye surgery business to Germany-based Carl Zeiss Meditec, Finanzen reported, citing Bloomberg.

The deal could be worth $2 billion for the drugmaker, which has been struggling under a debt burden—and a laundry list of other self-inflicted problems—for almost two years.

Valeant has been shopping various assets, promising to raise $8 billion, but it’s had a tough time finding buyers for some of them. A potential $10 billion deal to sell its big gastrointestinal drug unit, Salix, to Takeda, for example, fell apart in November.

Word of Valeant’s attempt to sell the Bausch & Lomb unit emerged the same month. Zeiss was among the rumored buyers at the time, along with Allergan, which has a substantial eye business of its own, and the private equity firm TPG.

The Zeiss talks are at an early stage now, Bloomberg’s sources say, and may still fall apart. Other bidders may still be interested, too.

Valeant built up a mountain of debt, some $29 billion at last count, as it bought up company after company to grow sales and gin up profits with subsequent cost-cutting. That growth-by-M&A model relied partly on its ability to hike prices on the older meds it acquired in its buyouts, and that’s an ability since compromised by a firestorm of drug-pricing criticism.

That scrutiny was, of course, fueled by Valeant itself, after triple-digit hikes on some of its meds went public. The company quickly joined Turing Pharmaceuticals and its ex-CEO Martin Shkreli in the lineup of publicly reviled price-hike perpetrators.

Valeant soon faced federal investigations, its executives were forced to defend themselves on Capitol Hill, and a management shakeup saw ex-CEO Michael Pearson to the door. Its shares went into a nosedive and still trade at a fraction of their previous highs. A tiny fraction, in fact: From a high of more than $257 in July 2015, Valeant shares have plummeted to $12.64 as of Monday’s close.

Valeant has succeeded in offloading a few assets: In January, it sold Dendreon Pharmaceuticals to the Chinese drugmaker Sanpower for $820 million and some skin care brands to L’Oreal for about $1.3 billion. But a sale of its Australian subsidiary iNova hit a snag in April when bids came in around $900 million, lower than Valeant had expected.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).